SBIR Phase I: Surveyor Endonuclease Adaptor-Ligated Libraries for Genomic Mutation Analysis

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 0839635
Agency Tracking Number: 0839635
Amount: $99,353.00
Phase: Phase I
Program: SBIR
Awards Year: 2009
Solicitation Year: N/A
Solicitation Topic Code: BC
Solicitation Number: NSF 08-548
Small Business Information
Transgenomic, Inc.
12325 Emmet Street, Omaha, NE, 68164
DUNS: 969419258
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Gary Gerard
 BS
 (240) 631-2001
 ggerard@transgenomic.com
Business Contact
 Gary Gerard
Title: BS
Phone: (240) 631-2001
Email: ggerard@transgenomic.com
Research Institution
N/A
Abstract
This Small Business Innovation Research (SBIR) Phase I project develops a novel process allowing rapid and cost-effective analysis of genetic variation between test and known, control genomes. The method, known as SEAL, will allow researchers to construct DNA libraries containing only these variations. This would be a breakthrough in technology as whole genome sequencing produces vast amounts of redundant data representing the test genome?s regions that are identical to the control genome. Using current sequencing technologies this redundant data imposes high generation and analysis costs without contributing any new information. This project will demonstrate the method?s feasibility by developing robust bacterial genome analysis applications. Each step of the multi-staged method will be tested to find optimal conditions. Phase II aims will be developing more complex human genomic applications. The broader impacts of this research are on how DNA sequencing is performed and DNA variation is assessed. Research areas impacted include: pharmacogenomic assessment for personalized medicine diagnostics, notably in cancer treatment; simpler, less data-intensive methods to collect the genetic variation information required for understanding complex diseases, such as diabetes and cardiovascular disease, and tools for discovery of new antibiotics for drug-resistant pathogens. The commercial value will be a dramatic decrease in the cost and time of genome sequencing, identification of biomarkers associated with appropriate treatments and decreased requirements for very high cost sequencing equipment.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government